{"nctId":"NCT00074152","briefTitle":"Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer","startDateStruct":{"date":"2002-07"},"conditions":["Breast Cancer"],"count":162,"armGroups":[{"label":"Arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: radiation therapy"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Drug: chemotherapy"]}],"interventions":[{"name":"chemotherapy","otherNames":[]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n\n  * First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph node region) recurrence after primary treatment with mastectomy or lumpectomy/quadrantectomy with clear surgical margins\n\n    * Local failure is defined as a tumor recurrence in any soft tissue of the ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin\n    * Regional failure is defined as a tumor recurrence in the ipsilateral axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla, and/or ipsilateral internal mammary. Regional failure does not include supraclavicular lymph nodes or tumor in the opposite breast\n  * No other prior recurrence in any site, including local\n* Surgical resection of the recurrence meeting 1 of the following criteria:\n\n  * Uninvolved (\"clear\") margins and planned radiotherapy with at least 40 Gy for patients who had no prior adjuvant radiotherapy\n  * Mastectomy of the recurrence with uninvolved (\"clear\") margins after lumpectomy/quadrantectomy alone for the primary\n* Adjuvant trastuzumab (HerceptinÂ®) therapy or other HER-2 directed therapies are allowed for patients with HER-2 positive tumors and must be declared prior to randomization\n* No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes, by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is \\> 2 times normal or if medically indicated (e.g., bone pain)\n* No macroscopically incomplete surgery\n* No bilateral malignancy except carcinoma in situ\n* No suspicious mass in the opposite breast unless that mass has been proven by biopsy to be benign\n* No skeletal pain of unknown cause\n\n  * No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI, and/or CT scan\n* Hormone receptor status:\n\n  * Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding assay\n  * Estrogen receptor positive or negative\n  * Progesterone receptor positive or negative\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Minimum 18 years\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* Not specified\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* No elevated alkaline phosphatase\n\nRenal\n\n* Not specified\n\nOther\n\n* Fertile patients must use effective non-hormonal contraception\n* Medically suitable for chemotherapy of 3-6 months duration\n* No other primary malignant tumors except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer\n* No non-malignant systemic disease that would preclude study treatment or prolong follow-up\n* No psychiatric or addictive disorder that would preclude giving informed consent\n* No history of noncompliance to medical regimens or potential for being unreliable\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Disease Characteristics\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* See Disease Characteristics\n\nSurgery\n\n* See Disease Characteristics","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disease-free Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Sites of First Failures","description":"Tumor recurrence in the breast, lymph nodes or other areas of the body including bone, lung, liver, central nervous system, bone marrow","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":[]}}}